Episode Details

Back to Episodes
Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

Published 2 weeks, 6 days ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/scientists-protected-glaucoma-nerve-cells-without-lowering-eye-pressure-could-mitochondria-become-the-next-treatment-target

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target? Short answer: possibly—but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established. The study at the center of this question was first published in Advanced Science on October 18, 2026. Researchers used adeno-associated virus serotype 2 to increase A-kinase anchoring protein 1, or AKAP1, in the retina. Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain—even while their eye pressure remained elevated. The results support the idea of pressure-independent neuroprotection. They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable. The October 2026 Advanced Science paper () That distinction matters. A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying. A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both. The study did not test that harder question. What AKAP1 does AKAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place. It is normally attached to the outer membrane of mitochondria, the cell’s energy-producing structures. AKAP1 is not itself an energy-producing enzyme. Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival. One important partner is protein kinase A, or PKA. AKAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1. PKA-mediated phosphorylation of DRP1 at a particular site—serine 637 in the mouse numbering used in this work—usually makes DRP1 less able to drive mitochondrial fission. The calcium-sensitive enzyme calcineurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division. Earlier laboratory work found that loss of AKAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory-chain proteins, and signs of oxidative and cell-death stress. The earlier retinal AKAP1 study () Mitochondria need both fusion and fission. Fusion can help mitochondria share contents and maintain function. Fission helps separate damaged parts, support mitochondrial transport, and allow quality-control processes such as mitophagy. The goal is not simply “more fusion.” It is a healthy balance that changes appropriately with a cell’s needs. AKAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called cristae. But the new study did not show that AKAP1 physically binds OPA1. It showed that OPA1 levels changed along with AKAP1 treatment. The direct mechanistic case is stronger for the AKAP1–PKA–DRP1 relationship than for any direct AKAP1–OPA1 interaction. Mitochondria also help manage cellular calcium and supply energy for processes such as nerve signal

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us